Literature DB >> 15480415

Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion.

Catherine L Neary1, Maria Nesterova, Yee Sook Cho, Chris Cheadle, Kevin G Becker, Yoon S Cho-Chung.   

Abstract

The cAMP-dependent protein kinase types I (PKA-I) and II (PKA-II), composed of identical catalytic (C) subunits but distinct regulatory (R) subunits (RI versus RII), are expressed in a balance of cell growth and differentiation. Distortion of this balance may underlie tumorigenesis and tumor growth. Here, we used PC3M prostate carcinoma cells as a model to overexpress wild type and mutant R and C subunit genes and examined the effects of differential expression of these genes on tumor growth. Only the RIIbeta and mutant RIalpha-P (a functional mimic of RIIbeta) transfectants exhibited growth inhibition in vitro, reverted phenotype, and apoptosis, and inhibited in vivo tumor growth. DNA microarrays demonstrated that RIIbeta and RIalpha-P overexpression upregulated a cluster of differentiation genes, while downregulating transformation and proliferation signatures. Overexpression of RIalpha and Calpha, which upregulated PKA-I, elicited the expression signatures opposite that elicited by RIIbeta overexpression. Total colocalization of Calpha and RIIbeta seen by confocal microscopy in the RIIbeta cell nucleus supports the opposed genomic regulation demonstrated between Calpha and RIIbeta cells. Differential expression of PKA R subunits may therefore serve as a tumor-target-based gene therapy for PC3M prostate and other cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480415     DOI: 10.1038/sj.onc.1208165

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunits.

Authors:  Maria Nesterova; Ioannis Bossis; Feng Wen; Anelia Horvath; Ludmila Matyakhina; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2007-12-04       Impact factor: 5.958

Review 2.  A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2016-07-17       Impact factor: 5.547

3.  PKA-type I selective constrained peptide disruptors of AKAP complexes.

Authors:  Yuxiao Wang; Tienhuei G Ho; Eugen Franz; Jennifer S Hermann; F Donelson Smith; Heidi Hehnly; Jessica L Esseltine; Laura E Hanold; Mandi M Murph; Daniela Bertinetti; John D Scott; Friedrich W Herberg; Eileen J Kennedy
Journal:  ACS Chem Biol       Date:  2015-03-25       Impact factor: 5.100

4.  Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10.

Authors:  Li-Yan Khor; Kyounghwa Bae; Tahseen Al-Saleem; Elizabeth H Hammond; David J Grignon; William T Sause; Miljenko V Pilepich; Paul P Okunieff; Howard M Sandler; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

5.  Systematic comparison of gene expression between murine memory and naive B cells demonstrates that memory B cells have unique signaling capabilities.

Authors:  Mary M Tomayko; Shannon M Anderson; Catherine E Brayton; Saheli Sadanand; Natalie C Steinel; Timothy W Behrens; Mark J Shlomchik
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling.

Authors:  Madson Q Almeida; Michael Muchow; Sosipatros Boikos; Andrew J Bauer; Kurt J Griffin; Kit Man Tsang; Chris Cheadle; Tonya Watkins; Feng Wen; Matthew F Starost; Ioannis Bossis; Maria Nesterova; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2010-01-15       Impact factor: 6.150

7.  Protein kinase A regulatory subunit distribution in medulloblastoma.

Authors:  Carla Mucignat-Caretta; Luca Denaro; Marco Redaelli; Domenico D'Avella; Antonio Caretta
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

8.  8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth.

Authors:  Elisa Stellaria Grassi; Alessandra Dicitore; Irene Negri; Maria Orietta Borghi; Giovanni Vitale; Luca Persani
Journal:  Endocrine       Date:  2016-07-27       Impact factor: 3.633

9.  The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.

Authors:  Alan Pollack; Kyounghwa Bae; Li-Yan Khor; Tahseen Al-Saleem; M Elizabeth Hammond; Varagur Venkatesan; Roger W Byhardt; Sucha O Asbell; William U Shipley; Howard M Sandler
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  Selective distribution of protein kinase A regulatory subunit RII{alpha} in rodent gliomas.

Authors:  Carla Mucignat-Caretta; Andrea Cavaggioni; Marco Redaelli; Manuela Malatesta; Carlo Zancanaro; Antonio Caretta
Journal:  Neuro Oncol       Date:  2008-08-14       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.